Short Interest in NuCana plc (NASDAQ:NCNA) Rises By 73.9%

NuCana plc (NASDAQ:NCNA) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 144,300 shares, a growth of 73.9% from the December 15th total of 83,000 shares. Based on an average trading volume of 171,900 shares, the short-interest ratio is presently 0.8 days. Currently, 3.9% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc acquired a new position in shares of NuCana plc (NASDAQ:NCNA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned 0.57% of NuCana as of its most recent SEC filing. Institutional investors and hedge funds own 44.00% of the company’s stock.

NuCana Stock Performance

NCNA traded up $0.05 during trading on Wednesday, hitting $1.09. 22,955 shares of the stock were exchanged, compared to its average volume of 132,543. The firm has a 50 day simple moving average of $1.30 and a 200 day simple moving average of $2.60. The firm has a market cap of $2.88 million, a price-to-earnings ratio of -0.10 and a beta of 0.97. NuCana has a 1 year low of $0.96 and a 1 year high of $19.41.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.